drugset / Trial / NCT02155322
A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400)
NaSingle-groupOpen-labelTreatment
Summary
This study will assess the safety of Pegylated Interferon Alfa-2b (PEG-IFN) as an adjuvant treatment for melanoma.
Timeline
- Start
- 2014-08-19
- Primary completion
- 2016-03-21
- Completion
- 2016-03-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Peginterferon alfa-2b | Protein / enzyme biologic | 3 ug/kg | Subcutaneous |